# Tenofovir Disoproxil Fumarate (Tenofovir DF) Versus Emtricitabine/Tenofovir DF in Subjects Resistant to Lamivudine

> **NCT00737568** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 280 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **DRUG:** TDF
- **DRUG:** FTC/TDF
- **DRUG:** TDF Placebo
- **DRUG:** FTC/TDF Placebo

## Key facts

- **NCT ID:** NCT00737568
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2011-11
- **Final completion:** 2015-02
- **Target enrollment:** 280 (ACTUAL)
- **Last updated:** 2016-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00737568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00737568, "Tenofovir Disoproxil Fumarate (Tenofovir DF) Versus Emtricitabine/Tenofovir DF in Subjects Resistant to Lamivudine". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00737568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*